Navigation Links
Regeneron's Eylea Now Captures One-Quarter Of Wet AMD Patient Share, Surpassing Share Of Roche/Genentech's Lucentis

EXTON, Penn., Aug. 15, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed retinal specialists/general ophthalmologists now treat 26 percent of their intravitreal pharmaceutically treated wet age-related macular degeneration (AMD) patients with Regeneron's Eylea, a significant increase from one year ago. Eylea has been on the market since November 2011. In fact, patient share for Eylea now surpasses that for Roche/Genentech's Lucentis (21 percent), which has been available since 2006. However, off-label use of Roche/Genentech's Avastin continues to dominate the wet AMD market, largely due to its low cost relative to the other anti-vascular endothelial growth factor (VEGF) agents and proven efficacy.

According to the TreatmentTrends®: Dry/Wet AMD (US) report, physician preference for Eylea is likely driven by its convenient twice monthly dosing frequency, which is supported by the finding that wet AMD patients receive significantly fewer Eylea injections than Avastin or Lucentis injections during the first two years of treatment. Data from the report also suggest that Eylea is moving up in the wet AMD treatment algorithm and is now the most preferred branded therapy indicated for the treatment of wet AMD, with Lucentis being the typical third-line treatment option.

"This shift in Eylea use is likely motivated by prescribers' high satisfaction with the agent and their positive perceptions related to its efficacy," said BioTrends Research Group Senior Business Insights Analyst Emma Williams, Ph.D. "These perceptions will contribute to the continued growth of Eylea patient share over the next six months and will trail only Avastin's patient share."

Report findings also reveal that surveyed physicians rate geographic atrophy associated with dry AMD as the AMD disease type with the greatest need for new products, a finding which is not surprising given the high degree of vision loss suffered by these patients and the paucity of treatment options currently available for dry AMD. However, even as physicians acknowledge the high unmet need for dry AMD, few are aware of products in development for dry AMD, including Otsuka/Acucela's ACU-4429 and MacuCLEAR's MC-1101. Instead, awareness is higher for surveyed products in development for wet AMD, in particular Ophthotech's Fovista, Ohr Pharmaceuticals's squalamine and Allergan's anti-VEGF DARPin. Surveyed physicians perceive these products for wet AMD as having potential to provide the most value to the treatment of their AMD patients, largely due to Fovista's synergistic effect when administered with an anti-VEGF agent, squalamine's eye drop formulation and anti-VEGF DARPin's novel mechanism of action and duration of action.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Watching, Reading and Listening: A New Way to Interact with Patient Information
5. Phreesia identifies over 26% of patients who require additional autism evaluation
6. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinsons disease
10. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
11. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
Breaking Medicine Technology:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
Breaking Medicine News(10 mins):